Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol
<strong>Trial design</strong> We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment with the first-in-class co-stimulatory blo...
Autors principals: | Al-Laith, M, Jasenecova, M, Abraham, S, Bosworth, A, Bruce, I, Buckley, C, Ciurtin, C, D'Agostino, M, Emery, P, Gaston, H, Isaacs, J, Filer, A, Fisher, B, Huizinga, T, Ho, P, Jacklin, C, Lempp, H, McInnes, I, Pratt, A, Östor, A, Raza, K, Taylor, P, Van Schaardenburg, D, Shivapatham, D, Wright, A, Vasconcelos, J, Kelly, J, Murphy, C, Prevost, A, Cope, A |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
BioMed Central
2019
|
Ítems similars
-
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol
per: Mariam Al-Laith, et al.
Publicat: (2019-07-01) -
Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
per: Rakieh C, et al.
Publicat: (2014-04-01) -
Desarrollo de psoriasis durante el tratamiento con Abatacept en artritis reumatoidea
per: J.A. Riera, et al.
Publicat: (2019-06-01) -
Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy
per: Ofra Goldzweig, et al.
Publicat: (2011-01-01) -
THE EFFECT OF ABATACEPT ON BLOOD BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
per: M. A. Borisova, et al.
Publicat: (2017-09-01)